Touro Scholar
College of Osteopathic Medicine (TUN)
Publications and Research

College of Osteopathic Medicine

2015

SGLT2 Inhibitors for Type 2 Diabetes Mellitus Treatment
Raymond A. Plodkowski
Megan E. McGarvey
Heather M. Huribal
Keith Reisinger-Kindle
Bradley Kramer

See next page for additional authors

Follow this and additional works at: https://touroscholar.touro.edu/tuncom_pubs
Part of the Nutritional and Metabolic Diseases Commons, and the Pharmacy and Pharmaceutical
Sciences Commons

Recommended Citation
Plodkowski, R. A., McGarvey, M. E., Huribal, H. M., Reisinger-Kindle, K., Kramer, B., Solomon, M., & Nguyen,
Q. T. (2015). SGLT-2 inhibitors for the treatment of type 2 diabetes mellitus. Federal Practitioner, 32(Suppl.
11), 10S-17S.

This Article is brought to you for free and open access by the College of Osteopathic Medicine at Touro Scholar. It
has been accepted for inclusion in College of Osteopathic Medicine (TUN) Publications and Research by an
authorized administrator of Touro Scholar. For more information, please contact touro.scholar@touro.edu.

Authors
Raymond A. Plodkowski, Megan E. McGarvey, Heather M. Huribal, Keith Reisinger-Kindle, Bradley Kramer,
Mordecai Solomon, and Quang T. Nguyen

This article is available at Touro Scholar: https://touroscholar.touro.edu/tuncom_pubs/1

SGLT2 Inhibitors for Type 2
Diabetes Mellitus Treatment
Raymond A. Plodkowski, MD; Megan E. McGarvey, MD; Heather M. Huribal, MD;
Keith Reisinger-Kindle; Bradley Kramer; Mordecai Solomon, DO; and Quang T. Nguyen, DO

SGLT2 inhibitors are plausible second-line drugs that provide powerful additional A1c-lowering
effects while inducing weight loss without hypoglycemia.

O

ver the past 2 decades, the treatment of type 2
diabetes mellitus (T2DM) has been an evolving
science. With therapeutic advances, the prevalence of catastrophic complications such as amputations,
renal failure requiring dialysis, and blindness due to retinopathy have significantly declined. Developed drugs
have successfully met treatment goals; however, they are
often associated with a higher risk of hypoglycemia and
weight gain. Now that better glucose control is possible,
the science of diabetes care continues to evolve. Newly
developed drugs should control glucose without significant hypoglycemia and also promote weight reduction.
The sodium-glucose transport protein 2 (SGLT2) inhibitor drug class has these characteristics, and the novel
mechanism of action complements older medications
used to treat T2DM.
Phlorizin is a plant-based compound originally discovered in 1935 when it was derived from the bark of apple
trees.1 It is a naturally occurring botanical glucoside and is
fairly nonselective between SGLT1 and SGLT2. Due to its
poor bioavailability and its degradation in the gastrointestinal tract, it was not an ideal drug candidate in humans.
However, it stood as a starting point for the development
of the current gliflozin class of SGLT2 inhibitors canagliflozin, dapagliflozin, and empagliflozin, which are reviewed in this article. The Table outlines the differences
between the drugs. The eTable (available at www.fedprac
.com) highlights clinical trial data for each drug.

CANAGLIFLOZIN

Canagliflozin is a SGLT2 inhibitor and a low-potency
SGLT1 inhibitor. It was the first SGLT2 inhibitor approved by the FDA (March 2013) to be used with diet
and exercise to improve glycemic control in adults with
T2DM. The recommended starting dose is 100 mg once
daily for patients who have an estimated glomerular filtration rate (eGFR) > 60 mL/min/1.73m2 and can be
increased to 300 mg once daily. It is also available in a
fixed-dose combination with metformin. Canagliflozin
SGLT-2 inhibition leads to increased glycosuria and osmotic diuresis that lowers plasma glucose concentrations. Lower blood pressure (BP) is likely an effect of
the osmotic diuresis. Increased urinary excretion of glucose also leads to a loss of calories and weight loss. It was
studied alone and in combination with metformin, sulfonylurea, pioglitazone, and insulin therapy.
The pharmacokinetics of canagliflozin is similar in
healthy subjects and patients with T2DM. Peak plasma
concentrations (Cmax) and area under the cover (AUC)
of canagliflozin increased in a dose-proportional manner
from 50 mg to 300 mg. Following single-dose oral administration of 100 mg and 300 mg of canagliflozin, time
to Cmax (Tmax) of canagliflozin occurs within 1 to 2 hours
postdose. The apparent terminal half-life (t1/2) was
10.6 hours and 13.1 hours for the 100 mg and 300 mg
doses, respectively. Steady state was reached after 4 to
5 days of once-daily dosing with canagliflozin 100 mg to
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10 mg. There was a difference
of 0.42 (P = .0122), which was a
Canagliflozin Dapagliflozin
Empagliflozin
10.3% reduction in AUC PPGE
by canagliflozin compared with
Starting dose
100 mg qd
5 mg qd
10 mg qd
dapagliflozin.
Maintenance dose
300 mg qd
10 mg qd
25 mg qd
Canagliflozin has been studied in
2
patients
with T2DM and stage 3 ne< eGFR (mL/min/1.73 m )
< 45
< 60
< 45
phropathy.
Data were pooled from 4 rannot recommended
domized, placebo-controlled, phase 3
SGLT1 effects
Yes
No
No
studies in which subjects had baseline
Abbreviations: eGFR, estimated glomerular filtration rate; qd, once daily; SGLT, sodium-glucose
eGFR > 30 to < 60 mL/min/1.73 m2.4
transport protein.
In the setting of decreased eGFR associated with stage 3 chronic kidney disease,
300 mg. Glucuronidation is the major metabolic pathway.
subjects treated with canagliflozin 100 mg and canagliflozin
There is balanced renal and biliary excretion of metabo300 mg had placebo-subtracted reductions in hemoglobin
lites, and there are no active metabolites.
A1c (A1c) of -0.38% and -0.47%, respectively, and placeboFollowing oral doses of canagliflozin in patients with
subtracted reduction in weight of -1.6% and -1.9%, respecT2DM, dose-dependent decreases were seen in the renal
tively. Decreases in eGFR were seen at week 6 but trended
threshold for glucose (RTG). From a starting value of
toward baseline over time with a mean change in eGFR of
about 240 mg/dL, the 300-mg dose suppressed the mean
0.7, -1.7, -2.2 mL/min/1.73 m2 for placebo, canagliflozin
(RTG) to about 70 to 90 mg/dL in T2DM in phase 1
100 mg, and canagliflozin 300 mg, respectively.
studies. The reduction in RTG led to increase in urinary
excretion of glucose of about 100 g/d.
Clinical Efficacy Trials
In addition to renal SGLT2 inhibition leading to inCanagliflozin was studied as add-on therapy to metcreased urinary glucose excretion (UGE), canagliflozin
formin and compared with glimepiride (a sulfonylhas been shown to lower postprandial glucose excururea).5 The randomized, double-blind study included
sion (PPGE) and insulin concentrations by delaying
1,450 subjects for a core study period of 52 weeks folintestinal glucose absorption.2 A study was done in
lowed by a 52-week extension. Eligible subjects were
20 healthy subjects who received either placebo or
aged > 18 and < 80 years, A1c > 7% and < 9.5%, and
canagliflozin 300 mg 20 minutes before a 600 kcal
were receiving metformin > 2,000 mg/d or > 1,500 mg/d
mixed-meal tolerance test. Compared with placebo,
if unable to tolerate a higher dose. The study groups
canagliflozin reduced PPGE and insulin excursions
were canagliflozin 100 mg, canagliflozin 300 mg, and
(0-2 h) AUC by 35% and 43%, respectively (P < .001
glimepiride, and baseline A1c measurements were 7.78%,
for both). This may present a difference between cana7.79%, and 7.83%, respectively. The glimepiride was tigliflozin and the other SGLT2 inhibitors.
trated up if > 50% of fasting blood glucose measureBecause of the potential differences due to canaments were > 108 mg/dL with no hypoglycemic events
gliflozin’s inhibition of intestinal SGLT1, the pharmacodyin the previous 2 weeks.
namic differences between canagliflozin and dapagliflozin
Over 104 weeks, canagliflozin 100 mg and 300 mg
were studied.3 The randomized, double-blind, crossover
and glimepiride reduced A1c from mean baseline valstudy consisted of 54 subjects. The subjects received the
ues by -0.65%, -0.74%, and -0.55%, respectively, and
maximum approved doses of canagliflozin 300 mg or
the proportions of patients achieving A1c < 7% at week
dapagliflozin 10 mg a day. Each group was treated with the
104 was 42.5%, 50.2%, and 43.9%, respectively. Weight
study drug for 2 days, and then a 600 kcal mixed-meal tolfell over 104 weeks with canagliflozin 100 mg (-4.1%,
erance test was performed. The results of the PPGE 0- to
-3.6 kg) and canagliflozin 300 mg (-4.2%, -3.6 kg). In
2-hour AUC analysis showed 3.66 mmol*h/L with canacontrast, glimepiride showed weight increase (0.9%,
gliflozin 300 mg and 4.08 mmol*h/L with dapagliflozin
0.8 kg). Documented hypoglycemia episodes were

Table. SGLT2 Inhibitor Drugs

www.fedprac.com

OCTOBER 2015

•

FEDERAL PRACTITIONER

•

11S

SGLT2 INHIBITORS

lower in canagliflozin 100 mg and 300 mg than with
glimepiride (6.8%, 8.2%, and 40.9%, respectively).
A study was undertaken to compare canagliflozin
with the dipeptidyl peptidase-4 (DPP-4) inhibitor sitagliptin in patients with T2DM on background therapy of metformin.6 This randomized, double-blind trial
studied subjects aged > 18 and < 80 years with inadequate glucose control A1c > 7% and < 10.5%. Subjects
received metformin > 2,000 mg/d or > 1,500 mg/d if
unable to tolerate a higher dose. At week 52, canagliflozin showed noninferiority to sitagliptin, with both
drugs lowering A1c by 0.73%. Canagliflozin 300 mg
showed superiority to sitagliptin with -0.88% change
in A1c. Both canagliflozin 100 mg and 300 mg were superior to sitagliptin 100 mg in weight reduction: -3.8%,
-4.2%, and -1.3%, respectively. Genital mycotic infections were higher in the canagliflozin groups. Rates for
mycotic infections for sitagliptin 100 mg, canagliflozin
100 mg, and canagliflozin 300 mg were 1.2%, 5.2%,
and 2.4% in men, respectively, and 2.6%, 11.3%, and
9.9% in women, respectively.
Canagliflozin was also studied in combination with
insulin to determine efficacy and safety in this setting.7
Subjects were randomized to receive placebo, canagliflozin 100 mg, or canagliflozin 300 mg. Subjects had
a mean baseline A1c of 8.3%. The median daily insulin
dose was 60 IU, and most individuals were using basal/
bolus regimens. The primary endpoint was 18 weeks
of therapy, and A1c was lowered 0.62% (P < .001) with
canagliflozin 100 mg and 0.73% with canagliflozin
300 mg compared with placebo. Weight decreased 1.9%
(P < .001) with canagliflozin 100 mg and 2.4% (P < .001)
with canagliflozin 300 mg compared with placebo.
Adverse Effects and Precautions

Canagliflozin adverse effects (AEs) were generally low.
In the aforementioned 104-week study comparing canagliflozin 100 mg, canagliflozin 300 mg, and glimepiride,
AEs leading to discontinuation were low at 6.2%, 9.5%,
and 7.3%, respectively. Serious AEs were lower in the
canagliflozin 100 mg and 300 mg groups compared with
glimepiride at 9.7%, 9.7%, 14.3%, respectively.5
Limitations for use of canagliflozin are T1DM and diabetic ketoacidosis (DKA). In mild renal impairment,
there is no dose adjustment in patients with eGFR
> 60 mL/min/1.73 m2. In moderate renal impairment
(eGFR 45-60 mL/min/1.73 m2), dose is limited to 100 mg
once daily. It is recommended not to initiate canagliflozin
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if eGFR is < 45 mL/min/1.73 m2. Canagliflozin is contraindicated if eGFR is < 30 mL/min/1.73 m2.8
DAPAGLIFLOZIN

Dapagliflozin is a highly selective SGLT2 inhibitor. It is
a 1,400-fold greater inhibitor of SGLT2 vs SGLT1 and
was approved in January 2014. It is indicated as an adjunct to diet and exercise to improve glycemic control
in adults with T2DM. The recommended starting dose
is 5 mg once daily, taken in the morning, with or without food, and the dosage can be increased to 10 mg once
daily in patients who require additional glycemic control. Dapagliflozin should not be initiated if eGFR is
< 60 mL/min/1.73 m2, and it should be discontinued if
eGFR is persistently < 60 mL/min/1.73 m2.
By inhibiting SGLT2, dapagliflozin reduces reabsorption of filtered glucose and lowers the renal threshold for
glucose, thereby increasing UGE. Increased glucose secretion also leads to weight reduction. Dapagliflozin has
been studied alone and in combination with glipizide,
glimepiride, pioglitazone, and a DDP-4 inhibitor and as
an add-on to insulin with and without other oral antidiabetic drugs. It is also available in a fixed-dose combination with metformin.
Following oral administration of dapagliflozin, the
Tmax is usually attained within 2 hours under a fasting
state. The Cmax and AUC values increase the dose proportionally with increase in dapagliflozin dose in the
therapeutic dose range. The absolute oral bioavailability of dapagliflozin following the administration of a
10-mg dose is 78%. The mean plasma t1⁄2 for dapagliflozin is about 12.9 hours following a single oral
dose of 10 mg. In patients with normal renal function, the renal glucose excretion was 85 g per day at
maximal dose. In humans, 75% of the dose of dapagliflozin is primarily metabolized through the uridine
diphosphate glucuronosyltransferase 1A9 pathway.
Dapagliflozin and related metabolites are primarily
eliminated via the renal pathway.9
Clinical Efficacy Trials

Dapagliflozin was studied as add-on therapy to metformin with glipizide (a sulfonylurea) as the comparator.10
This 52-week double-blind, multicenter, active-controlled,
noninferiority trial randomized 801 patients. Eligible subjects were aged > 18 years with A1c > 6.5% and < 10%
and were receiving metformin or metformin and 1 other
oral antidiabetic drug up to half-maximal dose for at least
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8 weeks. During an 18-week titration period, all patients
started dapagliflozin 2.5 mg/d and glipizide 5 mg/d. At
21-day intervals, patients were titrated up to the next dosage level if fasting plasma glucose was > 110 mg/dL. Dapagliflozin could be titrated to 5 mg and then 10 mg per
protocol. Glipizide could be titrated to 10 mg or 20 mg
per protocol.
The A1c change with dapagliflozin was noninferior
to glipizide at week 52. The A1c adjusted mean change
from baseline was -0.52 for both dapagliflozin and glipizide. The secondary endpoint was weight change. The
glipizide group had a +1.44 kg weight gain, whereas the
dapagliflozin group had a -3.22 kg weight loss. The number of patients with ≥ 1 episode of hypoglycemia, either
symptomatic or with no symptoms, with blood glucose
≤ 63 mg/dL was assessed. The dapagliflozin group had a
3.5% rate compared with the glipizide group, which had
a 40.8% rate of patients with > 1 hypoglycemic episode.
A study examined the efficacy and safety of dapagliflozin in combination with and also vs a DPP-4 inhibitor with metformin background therapy. The study
looked at add-ons of saxagliptin plus dapagliflozin vs saxagliptin or dapagliflozin added alone.11 This was a randomized, double-blind, 24-week study with patients aged
> 18 years with inadequate glucose control A1c > 8.0%
and < 12.0%. Patients had to be on a stable dose of metformin > 1,500 mg/d for at least 8 weeks. Patients were
randomized 1:1:1 to receive either saxagliptin 5 mg/d and
dapagliflozin 10 mg/d plus metformin, saxagliptin 5 mg/d
and placebo plus metformin, or dapagliflozin 10 mg/d
and placebo plus metformin.
The patients had a mean age of 54 years and a mean
duration of T2DM of 7.6 years. The mean baseline A1c
was 8.94%. The addition of saxagliptin plus dapagliflozin
to metformin resulted in significantly greater A1c reduction compared with saxagliptin plus metformin or dapagliflozin plus metformin from baseline A1c levels: -1.47%,
-0.88%, -1.2%, respectively.11
Dapagliflozin was also studied in combination with
insulin to determine the safety and efficacy in this setting.12 This double-blind, placebo-controlled, parallel-group trial had an initial study period of 24 weeks
followed by an extension period totaling 104 weeks. At
48 weeks, patients on dapagliflozin 5 mg were switched
to 10 mg. Outcomes over 104 weeks were changed from
baseline A1c, insulin dose, and body weight. Up-titration of insulin was permitted if at least 3 self-monitored
blood glucose readings from the 7 days prior to the study
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visit were > 240 mg/dL up to week 12; > 220 mg/dL between weeks 12 and 24; > 178 mg/dL or if A1c was > 8%
between weeks 24 and 48. Between weeks 52 and 65,
insulin titrated up was allowed if A1c was > 7.5% and
between weeks 78 and 104 if A1c was > 7%. Insulin could
be titrated down if ≥ 2 self-monitored blood glucose readings were < 68 mg/dL.
The study group had a T2DM diagnosis for 13.6 years
and a mean duration of insulin therapy for about 6 years.
The mean daily insulin dose was 77.1 IU. The mean baseline A1c was 8.5%. At 104 weeks, the differences from placebo in A1c adjusted mean change from baseline were
-4.0% (P = .0002) and -0.4% (P = .0007) in the dapagliflozin 5 mg (switched to 10 mg at week 48) and 10 mg
groups, respectively. Insulin requirements increased progressively in the placebo group +18.3 IU/d at 104 weeks.
Insulin requirements stayed stable over 104 weeks in the
dapagliflozin groups. Body weight increased in the placebo group, whereas it decreased in the dapagliflozin
groups. At 104 weeks, the weight changes from baseline
in placebo, dapagliflozin 5 mg/10 mg, and dapagliflozin
10 mg were -0.99 kg, -1.03 kg (P < .001), and -1.5 kg
(P < .0001), respectively. The frequency of ≥ 1 minor
or major episodes of hypoglycemia was fairly balanced
across placebo, dapagliflozin 5 mg/10 mg, and dapagliflozin 10 mg at 61.9%, 61.3%, and 60.7%, respectively.
Adverse Effects and Precautions

Dapagliflozin was generally well tolerated. In the trial of
dapagliflozin compared with glipizide in the setting of
metformin background therapy, AEs led to discontinuation rates of 9.1% vs 5.9%, respectively. Serious AEs were
lower in the dapagliflozin group compared with glipizide
at 8.6% vs 11.3%, respectively.10
Limitations for use of dapagliflozin are the treatment of T1DM or the treatment of DKA. Dapagliflozin
should not be initiated in patients with an eGFR
< 60 mL/min/1.73 m2. No dose adjustment is needed in
patients with mild renal impairment (eGFR of ≥ 60 mL/
min/1.73 m2), and dapagliflozin should be discontinued when eGFR is persistently < 60 mL/min/1.73 m2. In
the clinical trials, there was an imbalance in the number of bladder cancer reported with dapagliflozin compared with placebo. Across 22 clinical studies, newly
diagnosed cases of bladder cancer were reported in
10 of 6,045 patients (0.17%) treated with dapagliflozin
and 1 of 3,512 patients (0.03%) treated with placebo or
a comparator.9 There were too few cases to determine
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whether the emergence of these events is related to dapagliflozin. Product labeling states dapagliflozin should
not be used in patients with active bladder cancer and
should be used with caution in those with a prior history
of bladder cancer.
EMPAGLIFLOZIN

Empagliflozin is the most recently FDA-approved SGLT2
inhibitor (August 2014) for improved glycemic control in
T2DM. It has the highest SGLT2 selectivity: > 2,500-fold
selectivity for SGLT2 over SGLT1.13 Empagliflozin regulates blood glucose levels by increased UGE, independent of endogenous insulin secretion. It is associated with
modest reductions in body weight, visceral adiposity, and
systolic BP.
Empagliflozin is available in 10-mg and 25-mg tablets,
with a recommended initial dose of 10 mg daily.13 Dosing adjustments are not required for geriatric patients or
for those patients with hepatic impairment.14 The use of
empagliflozin is contraindicated in patients with eGFR
< 45 mL/min/1.73 m2 or for those whose eGFR declines
to < 45 mL/min/1.73 m2 during therapy.15,16 Empagliflozin
has a pregnancy risk category C. Drug transference during lactation is unknown; therefore, empagliflozin during
breast-feeding is not recommended. It is also available in a
fixed-dose combination with metformin.
Empagliflozin has been studied alone and in combination therapy with other oral antidiabetic drugs as
well as insulin therapy. Metformin, pioglitazone, sitagliptin, and linagliptin have been studied in combination with empagliflozin with sustained glycemic
improvement without significantly increased risk of
hypoglycemia.17-21 Empagliflozin/linagliptin combination was recently approved after phase 3 trials demonstrated 62% of patients achieved an A1c value < 7%
on the 25/5-mg dose at 24 weeks.21 Empagliflozin, coadministered with multiple daily injections of insulin (MDI), has been shown to safely improve glycemic
control and reduce total daily insulin requirements
without an increased risk of hypoglycemia.22 Currently,
it is not approved for use in patients with T1DM, but
phase 3 trials are ongoing.
Pharmacokinetics of empagliflozin among healthy
volunteers paralleled those of people with T2DM with
rapid absorption. The plasma glucose lowering effect
of empagliflozin was evident after the first dose and became more pronounced with treatment duration. The
AUC and Cmax were dose-proportional over a range of
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empagliflozin doses in a single rising dose study, with
maximum UGE of 90.8 g in healthy volunteers reached
at the 400-mg dose.23 The Tmax was 1.5 to 2.1 hours after
dosing, comparable to dapagliflozin.24 Steady state with
once-daily dosing is reached by day 5 with t1/2 range
of 10 to 19 hours.24-27 Plasma levels of empagliflozin
declined in a biphasic pattern, with a rapid distribution phase and a slower elimination phase. Total urine
volume did not differ significantly in the empagliflozin
group compared with placebo.
Healthy subjects treated with placebo or empagliflozin
had comparable plasma glucose concentrations. Patients
with T2DM demonstrated a decrease in mean daily glucose of -37.0 mg/dL for the 10-mg dose compared with
-13.5 mg/dL for placebo. Doses up to 10 mg were found
to inhibit renal tubular reabsorption up to 40%, and
higher doses inhibit up to 60% of filtered glucose.22-26
Empagliflozin has been shown to have similar efficacy
independent of food.27 The pharmacodynamic response
declines with increasing renal impairment in SGLT2 inhibitors. Empagliflozin has been associated with a decline
from UGE of 97.6 g in normal renal function to 18.2 g in
severe renal impairment.
Phase 1 studies of healthy male volunteers initially
elucidated empagliflozin’s therapeutic potential of dosedependent increases in UGE and associated reduction in
A1c with daily administration, respectively.24,28 Single rising dose studies further defined the linear pharmacokinetics and excellent tolerability of empagliflozin.23 Heise
and colleagues demonstrated in 2 separate studies with
multiple oral doses (2.5 mg, 10 mg, 25 mg, and 100 mg)
of empagliflozin in people with T2DM similar pharmacokinetics and efficacy in UGE, tolerability, and reduction
in plasma glucose.24
Ferrannini and colleagues, in a 12-week phase 2 study,
demonstrated a statistically significant reduction in A1c of
0.5% and 0.6% with 10-mg and 25-mg doses, respectively,
as well as a universal body weight decline by 2 kg.29
Clinical Efficacy Trials

A phase 3 trial of 1,549 randomized people with T2DM
(aged > 18 years with baseline A1c of 7%-10%), comparing
empagliflozin and glimepiride as an add-on to metformin,
demonstrated noninferiority at 52 weeks and statistically significant superiority for the empagliflozin group
at 104 weeks.30 The adjusted mean difference in change
from baseline in A1c with empagliflozin vs glimepiride
at week 104 was -0.11% (95% confidence interval,
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-0.19 to -0.02; P = .0153 for superiority). Despite 39%
of both groups achieving a A1c < 7% at week 52, the
empagliflozin group had significantly less hypoglycemia (2% vs 24%). In the body composition substudy,
empagliflozin demonstrated a significant reduction of
3 kg compared with an increase of slightly over 1 kg in
the glimepiride group at week 104. The majority of the
empagliflozin-associated weight loss was found to be a
reduction in fat mass.
An international phase 2B randomized, controlled,
open-label extension study of 659 people with T2DM
(aged > 18 and < 79 years with a body mass index (BMI)
< 40 kg/m2 and baseline A1c of 7%-10%) described the
long-term safety and efficacy of empagliflozin monotherapy in combination with metformin as compared with sitagliptin monotherapy in combination with metformin.
At week 90, the changes from baseline A1c were -0.34%/
-0.47% in the empagliflozin 10 mg/25 mg monotherapy
group, -0.34%/0.63% in the empagliflozin 10 mg/25 mg/
metformin combination, -0.56% with metformin monotherapy, and -0.40% with sitagliptin/metformin combination.31 These data provided evidence that empagliflozin
had sustained weight loss effects (-2.2 kg to -4.0 kg).
Empagliflozin monotherapy was studied with sitagliptin as an active comparator in a phase 3 trial of
899 people with T2DM (aged > 18 years with baseline
A1c of 7%-10%), with the primary endpoint of change in
baseline in A1c at week 24. Both the 10-mg and 25-mg
dose sof empagliflozin were associated with greater reductions in A1c from baseline (-0.66%, -0.77%) at week
24 than that of sitagliptin (-1.04%). Additionally, both
doses of empagliflozin were associated with greater reductions in bodyweight (-2.26 kg and -2.48 kg) as compared with sitagliptin 100 mg (+0.18 kg).20
Empagliflozin’s efficacy and safety in combination
with MDI insulin as well as add-on to basal insulin was
tested in 2 separate studies.23,32 People with T2DM (mean
age 58.8 years, A1c 8.2%) on basal insulin were randomized to empagliflozin (10 mg or 25 mg) or placebo for
78 weeks with a constant basal insulin dose for the first
18 weeks and titration allowed thereafter. Empagliflozin
was found to significantly reduce A1c at both 18 and
78 weeks (-0.48% and -0.64% for 10-mg/25-mg doses,
respectively, vs -0.02% for placebo) and insulin dose at
week 78 vs placebo (-8.8 IU on empagliflozin 10 mg
and -11.2 IU on empagliflozin 25 mg).32 Similar rates of
hypoglycemia were reported (36.1% of patients on
empagliflozin and 35.3% on placebo).
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Furthermore, empagliflozin was studied in obese
people with uncontrolled, insulin-dependent T2DM
(A1c 8.3%, BMI 34.8 kg/m2) on MDI insulin (average
92 IU/d) over a 52-week study.22 Patients were randomized to once-daily empagliflozin 10 mg, empagliflozin
25 mg, or placebo. The study demonstrated improved
glycemic control (A1c reduction of -1.27% and -1.18%
on empagliflozin 10 mg and 25 mg doses, respectively,
compared with -0.81% on placebo) with lower insulin doses (-9 to -11 IU/d) and weight loss (-1.95 kg and
-2.04 kg on empagliflozin 10-mg and 25-mg doses, respectively, compared with 0.44 kg on placebo.) There
was no increased risk of hypoglycemia noted.
Adverse Effects and Precautions

Empagliflozin is generally well tolerated with low occurrence of AEs. Adverse effects reported in the pooled
empagliflozin phase 3 studies were mild to moderate. Serious AEs reported were higher in the placebo group as
compared with those of the empagliflozin subjects but
did not result in study discontinuation.33
Drug-drug studies of empagliflozin co-administered
with other commonly prescribed medication in T2DM
showed very limited, if any, interaction. Empagliflozin
had no effect on the pharmacokinetics of warfarin or on
its anticoagulant activity; therefore, these 2 drugs were
deemed safe to be co-administered. No AEs were reported when combining empagliflozin with the loop diuretic hydrochlorothiazide.33 Due to the mode of action
of SGLT2 inhibitors, osmotic diuresis may result in a
modest reduction in BP.34
The FDA recently released a warning that SGLT2
inhibitors may be associated with a higher risk of developing DKA. 35 The FDA Adverse Event Reporting System identified 20 cases of DKA in patients
treated with SGLT2 inhibitors from March 2013 to
June 6, 2014. Diabetic ketoacidosis is typically accompanied by levels of ketone bodies > 3,000 μmol/L and
develops almost exclusively in states of absolute insulin deficiency. The highest level of ketone bodies observed in patients receiving 25 mg of empagliflozin was
1,449 μmol/L compared with a mean of 1,300 μmol/L
in a nondiabetic overnight fast.36 Therefore, it is unlikely
that the modest empagliflozin-induced ketosis would
increase the risk of developing DKA in the absence
of absolute insulin deficiency or extreme ketogenic
diet.37 Physiologic explanation at the present time is
not clear.

OCTOBER 2015

•

FEDERAL PRACTITIONER

•

15S

SGLT2 INHIBITORS

CLINICAL APPLICATION

The SGLT2 inhibitors are the latest of 14 classes of drugs
approved to treat T2DM. This class offers many beneficial
characteristics besides blood sugar lowering. The drugs
lower systolic BP, induce weight loss through diuresis of
glucose (calories), and carry low risks for hypoglycemia.
The American Association of Clinical Endocrinologists
recently published their 2015 diabetes management algorithm.38 In this algorithm, they recognized metformin as
first-line therapy along with diet and exercise intensification for the treatment of T2DM.
The glucagon-like peptide-1 (GLP-1) analogs and
SGLT2 inhibitors are recognized as plausible second-line
drugs. They go together well with metformin, providing
powerful additional A1c-lowering effects while inducing
weight loss without hypoglycemia. Because all GLP-1 analogs are currently available only in injectable forms, the
SGLT2 inhibitors offer the additional advantage of being
available in pill forms.
CONCLUSIONS

All 3 of the current SGLT2 inhibitors are effective tools
for treating T2DM. The 3 drugs share many similar traits,
and efficacy is generally similar. Empagliflozin has the
highest SGLT2 selectivity, > 2,500-fold selectivity for
SGLT2 over SGLT1. However, canagliflozin has mild
SGLT1 activity, which may offer additional benefits with
regards to attenuating PPGE excursions by delaying intestinal glucose absorption (Table).
The SGLT2 inhibitor class had been shown to be effective when used as monotherapy as well as in combination
with other oral antidiabetic medications. All 3 SGLT2 inhibitors have also been shown to be effective in combination with insulin and have similar efficacy in these
clinical settings (eTable).
All 3 SGLT2 inhibitors are generally well tolerated.
There is less hypoglycemia compared with sulfonylureas.
However, when the SGLT2 drugs are combined with drugs
that can cause hypoglycemia, such as sulfonylureas and insulin, patients must be monitored for hypoglycemia, and
titrating down the sulfonylurea or insulin may be necessary. Genital mycotic infections and urinary tract infections
in men and woman are common AEs with SGLT2 drugs.
Patients must be advised of these possible AEs, and treatment should be prompt if these AEs occur. Because of the
mild osmotic diuresis, patients should be reminded to keep
well hydrated. SGLT2s have a very mild effect on increasing
low-density lipoprotein cholesterol (LDL-C), so care should
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be taken to ensure that patients’ LDL-C stays at goal.
The FDA recently released a warning that SGLT2 inhibitors may be associated with a higher risk of developing DKA. Although these reports are rare, clinicians
should be vigilant. The FDA has suggested that patients
should pay close attention for any signs of DKA and seek
medical attention immediately if they experience difficulty breathing, nausea, vomiting, abdominal pain, confusion, and unusual fatigue or sleepiness.35
There are subtle differences in the eGFR thresholds for
the use of the 3 drugs. It should be kept in mind that with
all 3 drugs, the efficacy decreases as the eGFR decreases.
It is recommended not to initiate canagliflozin if the patient’s eGFR is < 45 mL/min/1.73 m2. Dapagliflozin should
not be initiated in patients with an eGFR < 60 mL/min/
1.73 m2. Empagliflozin should not be initiated in patients
with an eGFR < 45 mL/min/1.73 m2.
The SGLT2 inhibitors are useful tools to lower blood
glucose levels in people with T2DM. They can be used as
monotherapy or in combination. They also cause weight
reduction. Thus, their unique mechanism of action is
complementary to the other oral antidiabetic medications
and insulin, so a wide variety of patients can benefit from
this class. 
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